Seborrheic Dermatitis on the Scalp: Symptoms & Treatment

What Is Seborrheic Dermatitis of the Scalp?

Seborrheic dermatitis (SD) is a common, chronic inflammatory skin condition that primarily affects areas of the body richest in sebaceous (oil) glands — the scalp, face, ears, and upper chest. On the scalp, it produces the most visible and troublesome presentation: greasy or dry scales, visible redness, and persistent itch.

SD sits at the more severe end of a clinical spectrum that includes simple dandruff at one extreme and severe, body-wide disease in immunocompromised individuals at the other. The unifying biology is the same — Malassezia yeast interacting with sebum and the host immune system — but the inflammation and extent distinguish SD from ordinary dandruff.

Key distinguishing features of seborrheic dermatitis vs. dandruff:

Who Is Affected?

Seborrheic dermatitis affects approximately 3–10% of the general adult population (estimates vary by diagnostic criteria used). Key epidemiological patterns:

• Age: Bimodal distribution — peaks in infancy (cradle cap, affecting up to 72% of babies at 3 months) and in adults after age 40; increases further in the elderly
• Sex: Males affected more commonly and severely than females, consistent with androgen-driven sebum production
• Immune status: SD is dramatically more prevalent and severe in immunocompromised individuals — affecting approximately 35% of people with early HIV and up to 85% of those with AIDS. Sudden-onset severe SD in a previously unaffected adult should trigger investigation for immune compromise
• Neurological conditions: People with Parkinson's disease have SD prevalence of 60–73%, one of the highest in any identified population — possibly due to altered sebum production and autonomic dysfunction

What Causes Scalp Seborrheic Dermatitis?

The pathogenesis is multifactorial and involves three interlocking mechanisms:

Malassezia Yeast and Lipid Metabolism

Malassezia — a lipophilic genus of yeast that is normal flora on every adult scalp — drives seborrheic dermatitis not merely through its presence but through what it does with sebum.

Scalp sebum is approximately 50–60% triglycerides. Malassezia secretes lipase enzymes that cleave these triglycerides, releasing free fatty acids — particularly oleic acid — onto the scalp surface. In susceptible individuals, these fatty acids penetrate the stratum corneum, triggering keratinocyte dysfunction and an inflammatory immune cascade.

The species most consistently implicated in scalp SD are Malassezia restricta and Malassezia globosa. A 2025 review found M. restricta abundance is elevated in SD-affected skin while total fungal diversity is reduced — suggesting a specific dysbiosis rather than simply elevated yeast counts.

Critically, the relationship between Malassezia and disease is not simply quantitative. Clinically healthy scalps also carry Malassezia. It is the individual immune response to fungal antigens that determines whether pathological inflammation occurs.

Immune Dysregulation

Emerging research has substantially reframed our understanding of seborrheic dermatitis immunopathology:

• NLRP3 inflammasome: M. globosa and M. restricta activate the NLRP3 inflammasome in keratinocytes and immune cells, triggering IL-1β secretion — a potent pro-inflammatory cytokine
• Th17/IL-23/IL-17 axis: γδ T cells produce IL-17 in response to Malassezia, and Th17 cell activation is now considered a central driver of chronic SD inflammation — similar to other inflammatory skin conditions such as psoriasis
• Mast cell histamine: Elevated histamine levels are documented in SD-affected skin, partly explaining the itch
• Elevated IFN-γ and IL-2: Detected in serum of SD patients, indicating systemic T-helper dysregulation

This immune-dysregulation model explains why SD is dramatically worsened by immunosuppression and why some patients with otherwise-controlled SD experience rapid improvement with immunomodulatory therapies.

Epidermal Barrier Dysfunction

Genetic variation in barrier proteins — including filaggrin and other structural components of the stratum corneum — creates permeability that allows Malassezia-derived fatty acids and other antigens to penetrate more readily. Barrier dysfunction and inflammation become mutually reinforcing: inflammation damages the barrier, which allows more antigen exposure, which perpetuates inflammation.

Symptoms of Scalp Seborrheic Dermatitis

Scalp SD produces a characteristic presentation:

• Greasy or dry scaling — yellowish, often adherent flakes or sheets of scale, larger and more cohesive than simple dandruff flakes
• Erythema (redness) — visible reddening of the scalp, sometimes extending to the hairline
• Pruritus (itch) — typically moderate to severe; more prominent than in dandruff
• Burning sensation — reported by some patients, particularly on the face and ears
• Extension beyond the scalp — in SD (unlike dandruff), involvement may spread to:
  • Eyebrows and glabella (between the brows)
  • Sides of the nose and nasolabial folds
  • External ear canals and behind the ears
  • Beard area in men
  • Upper chest and skin folds (more common in severe or immunocompromised cases)

Severe SD of the scalp may produce thick, crusted plaques that mat hair and, if untreated, can develop secondary bacterial or yeast infection.

Diagnosis

Seborrheic dermatitis is diagnosed clinically — based on the characteristic distribution, scale morphology, and erythema. Investigations are rarely needed for typical presentations.

In atypical cases, a dermatologist may perform:

• KOH microscopy of skin scrapings — to identify fungal elements (not usually necessary for SD but helps exclude tinea capitis/ringworm)
• HIV serology — recommended for adults with sudden, severe, widespread, or treatment-refractory SD
• Skin biopsy — occasionally needed to distinguish SD from psoriasis, contact dermatitis, or pityriasis rosea. Histopathology shows superficial perivascular lymphocytic infiltration with spongiosis and parakeratosis

Conditions that can mimic scalp SD:

Treatment: Evidence-Based Options

Scalp seborrheic dermatitis requires a staged approach matched to severity.

First-Line: Antifungal Shampoos

Ketoconazole 2% (Prescription) / 1% (OTC)

The best-evidenced single agent for scalp SD:

• Mechanism: Inhibits fungal ergosterol biosynthesis by blocking cytochrome P450-dependent enzymes; also alters scalp lipid composition reducing the substrate favoring Malassezia
• Efficacy: 73–89% improvement in dandruff/SD severity versus 29–44% with placebo across multiple double-blind trials; superior to zinc pyrithione with lower relapse rates
• Protocol: Twice weekly for 4 weeks (active treatment); once weekly for maintenance
• Safety: Generally well-tolerated; rare scalp irritation, dryness, or temporary hair texture change

Ciclopirox 1% Shampoo

A strong alternative and, in some studies, comparable or superior to ketoconazole:

• Reduces 12-week SD relapse rate to 14.7% versus 35.5% with vehicle control
• Twice-weekly application outperforms once-weekly in clearing active disease
• Good tolerability; local irritation is the main reported side effect

Zinc Pyrithione (1–2%) and Selenium Sulfide (2.5%)

Useful adjuncts and maintenance agents:

• Zinc pyrithione: Antifungal with a very low side-effect burden; primarily useful for maintenance after clearing with a stronger antifungal; clinical evidence base rated as limited quality
• Selenium sulfide 2.5%: Dual antifungal and cytostatic mechanism achieves 67% reduction in dandruff severity score versus 45% with placebo; higher cytostatic activity than some ketoconazole formulations in lab comparisons; side effects include scalp burning and risk of hair discoloration

Second-Line: Topical Corticosteroids

Corticosteroids rapidly reduce inflammation and itch but do not address the underlying fungal cause:

• Use: Short-term acute flare management only — typically 1–2 weeks
• Formulations: Scalp solutions, foams, or sprays containing betamethasone valerate 0.1%, fluocinolone acetonide, or clobetasol propionate 0.05%
• Risks: Prolonged scalp corticosteroid use risks skin atrophy, telangiectasia, and rebound flaring. Not appropriate for maintenance
• Combination approach: Using a topical antifungal concurrently with a short course of corticosteroid often clears active flares faster than either agent alone

Calcineurin Inhibitors (Tacrolimus, Pimecrolimus)

Steroid-sparing alternatives for patients who need anti-inflammatory treatment without corticosteroid risks:

• Effective for facial SD (where corticosteroid risks are highest) and as long-term maintenance
• Less commonly used on the scalp due to practical application limitations (thick hair reduces penetration)
• Not FDA-approved specifically for SD but are used off-label with clinical evidence

Systemic Antifungals

Reserved for widespread, severe, or treatment-refractory cases:

• Itraconazole 200 mg/day for 1 week/month: most studied oral option for SD; controls disease with maintenance dosing
• Fluconazole 300 mg once weekly: alternative with good evidence
• Terbinafine: effective against some Malassezia species but has more limited trial data for SD specifically

Emerging Therapies

A 2025 narrative review highlights active investigation of JAK inhibitors, PDE4 inhibitors, and biological therapies targeting the IL-23/IL-17 axis for moderate-to-severe SD. These remain experimental for SD and are not yet in clinical guidelines.

Practical Treatment Protocol

Active flare:

1. Start ketoconazole 2% shampoo twice weekly; leave on scalp for 5 minutes before rinsing
2. If itch is severe, a short course (1–2 weeks) of topical corticosteroid lotion or foam applied to the scalp can be added
3. Use a gentle, non-medicated everyday shampoo on non-treatment days if needed

Maintenance (once symptoms clear):

• Step down to ketoconazole 1% OTC, ciclopirox 1%, or zinc pyrithione shampoo once weekly
• Most adults need ongoing maintenance to prevent relapse — "cure" is not achievable, control is

Lifestyle adjuncts:

• Avoid heavy scalp oils and styling products that increase Malassezia substrate during active disease
• Manage psychological stress — a documented flare trigger
• Protect the scalp in cold, dry weather

Seborrheic Dermatitis in Skin of Color

SD presents differently across skin tones. In people with darker skin:

• Erythema (redness) is less visible — the inflammatory component may be missed or underestimated
• Post-inflammatory hypopigmentation — lighter patches after lesions resolve — is a common and distressing feature not typically seen in lighter skin
• Scale and itch remain the primary complaints
• Dermatologists should calibrate diagnostic thresholds accordingly; treatment principles are the same